MX2021013010A - Composiciones y metodos para modular la actividad del complemento. - Google Patents

Composiciones y metodos para modular la actividad del complemento.

Info

Publication number
MX2021013010A
MX2021013010A MX2021013010A MX2021013010A MX2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A
Authority
MX
Mexico
Prior art keywords
methods
complement
release formulations
modulate
compositions
Prior art date
Application number
MX2021013010A
Other languages
English (en)
Spanish (es)
Inventor
Hong Wang
Evan Thackaberry
Simon J Read
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of MX2021013010A publication Critical patent/MX2021013010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021013010A 2019-04-24 2020-04-24 Composiciones y metodos para modular la actividad del complemento. MX2021013010A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962837978P 2019-04-24 2019-04-24
US201962947183P 2019-12-12 2019-12-12
US201962947188P 2019-12-12 2019-12-12
PCT/US2020/029733 WO2020219822A1 (en) 2019-04-24 2020-04-24 Compositions and methods for modulating complement activity

Publications (1)

Publication Number Publication Date
MX2021013010A true MX2021013010A (es) 2022-01-18

Family

ID=70977557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013010A MX2021013010A (es) 2019-04-24 2020-04-24 Composiciones y metodos para modular la actividad del complemento.

Country Status (13)

Country Link
US (2) US20220211799A1 (cg-RX-API-DMAC10.html)
EP (1) EP3958842B1 (cg-RX-API-DMAC10.html)
JP (2) JP7726791B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220004039A (cg-RX-API-DMAC10.html)
CN (1) CN113710230A (cg-RX-API-DMAC10.html)
AU (1) AU2020261059A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021017820A2 (cg-RX-API-DMAC10.html)
CA (1) CA3137895A1 (cg-RX-API-DMAC10.html)
IL (1) IL287079A (cg-RX-API-DMAC10.html)
MX (1) MX2021013010A (cg-RX-API-DMAC10.html)
SG (1) SG11202109837SA (cg-RX-API-DMAC10.html)
TW (1) TW202106290A (cg-RX-API-DMAC10.html)
WO (1) WO2020219822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
SMT202100688T1 (it) 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
KR20260070290A (ko) 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
SG11202103972SA (en) * 2018-10-22 2021-05-28 Ra Pharmaceuticals Inc Neurological disease treatment with zilucoplan
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241139A (zh) * 1996-12-20 2000-01-12 武田药品工业株式会社 生产缓释制剂的方法
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CN1289066C (zh) * 2003-09-18 2006-12-13 中国人民解放军第二军医大学 胰高血糖素样肽-1缓释微球制剂及其用途
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
CN101374554A (zh) 2005-09-27 2009-02-25 埃弗拉特生物聚合物有限公司 胶凝疏水性可注射聚合物组合物
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10,顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
RU2009144142A (ru) 2007-04-30 2011-06-10 Алькон Рисерч, Лтд. (Us) Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
EP3089742A4 (en) * 2013-12-31 2017-08-02 Heron Therapeutics, Inc. Polymer-based compositions for extended release of proteins
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
WO2016138520A1 (en) 2015-02-27 2016-09-01 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
KR20260070290A (ko) * 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
US20170333304A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel Particles, Compositions, and Methods
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
DK3411400T3 (da) * 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet

Also Published As

Publication number Publication date
JP2025118607A (ja) 2025-08-13
CA3137895A1 (en) 2020-10-29
US20220211799A1 (en) 2022-07-07
SG11202109837SA (en) 2021-10-28
CN113710230A (zh) 2021-11-26
WO2020219822A1 (en) 2020-10-29
EP3958842B1 (en) 2026-07-29
EP3958842A1 (en) 2022-03-02
BR112021017820A2 (pt) 2022-02-08
TW202106290A (zh) 2021-02-16
JP7726791B2 (ja) 2025-08-20
KR20220004039A (ko) 2022-01-11
AU2020261059A1 (en) 2021-10-14
JP2022530042A (ja) 2022-06-27
IL287079A (en) 2021-12-01
US20260216276A1 (en) 2026-07-30

Similar Documents

Publication Publication Date Title
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2022002781A2 (es) Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2021000741A1 (es) Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
CL2020001990A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP22076856A (es) Inhibidores de rip1k
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2022000998A1 (es) Inhibidores de las cinasas raf
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY40873A (es) Compuestos cíclicos puenteados y composiciones farmacéuticas y usos de los mismos para modular la respuesta integrada al estrés y para tratar enfermedades relacionadas
CL2020001991A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1990-20)
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112021017820A2 (pt) Composições e métodos para modulação da atividade de complemento
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
ECSP19084085A (es) Inhibidores pirazólicos de magl
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX394098B (es) Compuestos inhibidores de ask1 y usos de los mismos
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.